Publications

* = corresponding author, †= research student/postdoc, # = authors contributed equally to the work

2026

• A Bayesian Adaptive Design for Avatar-Driven Cancer Clinical Trials. Biometrics (accepted).

• Raza, F., Gregorich, Z. R., Freeman, J., Moore, B., Houston, T., Garcia-Arango, M., ..., Park, Y., ..., & Guo, W. (2026). Multimodal Framework of Left Heart-Pulmonary Vascular Remodeling Underlying Right Ventricular Failure in PH-HFpEF. Circulation: Heart Failure, e014620. [link] 

• Lee, K., Park, Y., and Park, S. (2026). Reflective Hamiltonian Monte Carlo: Mixing Analysis and Application to Sampling on Stiefel Manifold. Proceedings of the 43rd International Conference on Machine Learning (ICML) 2026 [link] 

• Park, Y.* and Su, Z. (2026). ESPLSM: An Efficient and Interpretable Mediation Analysis Framework Using Sparse Envelopes. Statistics in Medicine [link] 

• Park, Y., Takeda, K, and Wei, Z.† (2026). A Randomized Dose-Ranging Basket Trial Design with Enrichment for Dose Optimization. Statistics in Biopharmaceutical research [link] 

• Jaclyn B. Dunne, Denys Rujchanarong, Yeonhee Park, Laura Spruill, Heather Jensen-Smith, Kristina Schwamborn, Michael Anthony Hollingsworth, Jade K. Macdonald, Taylor S. Hulahan, Harrison B. Taylor, George E. Sandusky, Anand S. Mehta, Richard R. Drake, Marvella E. Ford, Harikrishna Nakshatri, and Peggi M. Angel (2026). Spatial Proteomics of the Normal Breast Collagen Stroma: Links to Density and Body Mass Index. Journal of Proteome Research. 25. 1403-1419. [link] 

2025

• Chen, Y.† and Park, Y.* (2025+). Group Sequential designs for survival outcomes with adaptive randomization. Statistical Methods in Medical Research. [link]  

• Park, Y.* and Nycklemow, S.†  (2025). MARGO: Machine Learning-Assisted Adaptive Randomization for Group Sequential Trials based on Overlap Weights. Statistics in Medicine. [link] 

• Park, Y.* (2025). Optimal Two-stage Randomized Clinical Trial Designs based on Mann-Whitney-Wilcoxon test. Plos One. [link]

• Park, M., Park, Y., and Hung, H.M.James. (2025). Distribution of a P-Value When the Alternative Hypothesis is True for Binary Outcomes. Statistics in Biopharmaceutical research. [link]

• Park, Y.* and Xu, Z.† (2025) Data-driven monitoring for phase II clinical trial designs based on percentile event time test. Journal of Biopharmaceutical Statistics. [link] 

2024

• Park, Y.* (2024). Bias-corrected group sequential design in the presence of surrogate endpoints with application to PALM trial. Statistics in Biopharmaceutical research. [link]

• Park, Y.* and Chang, W. (2024). A Personalized Dose-finding Algorithm based on Adaptive Gaussian Process Regression. Pharmaceutical statistics. [link]

• Lee, K.† and Park, Y.* (2024). Bayesian Inference for Multivariate Probit Model with Latent Envelope. Biometrics. [link] 

• Taylor S. Hulahan, Laura Spruill, Elizabeth N. Wallace, Yeonhee Park, Robert B. West, Jeffrey R. Marks, E. Shelley Hwang, Richard R. Drake, Peggi M. Angel. (2024). Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics. International Journal of Molecular Sciences. [link] 

• Rujchanarong, D.,  Spruill,L., Sandusky, GE.,  Park, Y. , Mehta, AS., Drake, RR.,  Ford, ME., Nakshatri, H.,  Angel, P. (2024). Spatial N-glycomics of the normal breast microenvironment reveal fucosylated and high-mannose N-glycan signatures related to BIRADS density and ancestry. Glycobiology. [link] 

2023

• Park, Y.* and Chen, Y.† (2023). Sample Size Determination and Evaluation for Two-stage Adaptive Designs of Single-arm Clinical Trials based on Median Event Time Test. Contemporary Clinical Trials Communications. [link] 

• Konopka, A.R., Lamming, D.W., RAP PAC Investigators (including Park, Y.), and EVERLAST Investigators. (2023). Blazing a trail for the clinical use of rapamycin as a geroprotecTOR. GeroScience. [link] 

• Pozorski, V., Park, Y., Mohamoud, Y. Tesfamichael, D., Emamekhoo, H., Birbrair, A., Albertini, M., and Ma, V. (2023).  Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy. Pigment Cell & Melanoma Research. [link] 

• Shen, Y.†, Park, Y., Chakraborty, S., and Zhang, C. (2023). Bayesian Simultaneous Partial Envelope Model With Application to an Imaging genetics analysis. The New England Journal of Statistics in Data Science. [link] 

• Merrell, D.†, Chandereng, T., and Park, Y. (2023). A Markov Decision Process for Response-Adaptive Randomization in Clinical Trials. Computational Statistics and Data Analysis.  [link]

• Hess, B.#, Giri, A.#, Park, Y., Patel, K., Link, B., Nowakowski, G., Maliske, S. M., Fortin, S., Chavez, J., Saeed, H., Hill, B., Mejia-Garcia, A., Maddocks, K., Hanel, W., Wagner-Johnston, N. D., Messmer, M., Kahl, B., Watkins, M., Alderuccio, J., Lossos, I. S., Nathan, S., Orellana-Noia, V., Portell, C., Landsburg, D., Ayers, E., Amengual, J., and Castillo, J. J. (2023). Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. American Journal of Hematology. [link] 

2022

• Bakhtiar, H.#, Helzer, K.T.#, Park, Y., Chen, Y., Rydzewski, N.R., Bootsma, M., Sjöström, M., Lang, J.M., Yu, M., and Zhao, S.G. (2022). Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone across oncogenic pathways. npj Genomic Medicine. 7, 58. [link] 

• Park, Y.* (2022). Interval design to Identify the Optimal Biological Dose for Immunotherapy. Contemporary Clinical Trials Communications. [link] [ITIT R package]     

• Park, Y.*, Su, Z., and Chung, D. (2022).  Envelope-based Partial Partial Least Squares with Application to Cytokine-based Biomarker Analysis for COVID-19. Statistics in Medicine. [link]  [EPPLS_1.1 R package]

• Rujchanarong, D., Scott, D., Park, Y., Brown, S., Mehta, A.S., Drake, R., Sandusky, G.E., Nakshatri, H., and Angel, P. (2022). Metabolic Links to Socioeconomic Stresses Uniquely Affecting Ancestry in Normal Breast Tissue at Risk for Breast Cancer. Frontiers in Oncology, section Breast Cancer. [link] 

• Park, Y. and Liu, S. (2022). A Randomized Group Sequential Enrichment Design for Immunotherapy and Targeted Therapy.  Contemporary Clinical Trials. [link] 

• Miller, D., Livingston, J. A., Park, Y., Posey, K., Godbole, S., Skubitz, K., Robinson, S. I., Agulnik, M., Davis, L. E., Van Tine, B. A., Hirbe, A. C., Parkes, A.  (2022). Pregnancy Outcomes Related to the Treatment of Sarcomas with Anthracyclines and/or Ifosfamide During Pregnancy. Cancer Medicine. [link] 

• Park, Y.* (2022).  Personalized Risk-based Screening Design for Comparative Two-arm Group Sequential Clinical Trials. Journal of Personalized Medicine. [link]  

• Park, Y.* (2022). Challenges and Opportunities in Biomarker-Driven Trial Design: Adaptive Randomization. Annals of Translational Medicine.  (Editor-Invited. Special series on "Challenges in clinical trials"). [link] 

• Park, Y., Liu, S., Thall, P. F. and Yuan, Y. (2022). Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics. [link]  

2021

• Siegel, J.B., Mukherjee, R., Park, Y., Cluver, A.R., Chung, C., Cole, D.J., Lockett, M.A., Klauber-DeMore, N., and Abbott. A.M. (2021). Prognostic Factors for Residual Occult Disease in Shave Margins During Partial Mastectomy. Breast Cancer Research and Treatment. [link] 

• Park, Y.* (2021). Optimal Two-Stage Design of Single arm Phase II Clinical Trials based on Median Event Time Test. PLoS One. 16(2): e0246448. [link] [update] [METT R package] [shiny app]  

• Park, Y., Yuan, Y., Ning, J., Liu, S. and Feng, Z. (2021). Hybrid study design evaluating new markers when there is an existing screening test. Statistics in Medicine. [link] 

• Angel, P. M., Drake, R., Park, Y., Clift, C. L., West, C., Berkhiser, S., Hardiman, G., Mehta, A., Bichell, D., Su, Y. R. (2021). Spatial N-glycomics of the human aortic valve in development and pediatric endstage congenital aortic valve stenosis. Journal of Molecular and Cellular Cardiology. 154 P6-20. [link] 

• Asghari, G., Yuzbashian, E., Wagner, C.L., Park, Y., Mirmiran, P. and Hosseinpanah, F. (2021). Daily vitamin D3 in overweight and obese children and adolescents: a randomized controlled trial. European Journal of Nutrition. [link] 

• Alshareef, M., Lowe, S., Park, Y., and Frankel, B. (2021). Utility of Intraoperative Ultrasonography for Resection of Pituitary Adenomas: A Comparative Retrospective Study. Acta Neurochirurgica. [link] 

2020

• Park, Y. and Liu, S. (2020). On the coherence of dose-finding design for drug combination clinical trials. PLoS One 15(11): e0242561. [link] 

• Maser, T., Zagorski, J., Kelly, S., Ostrander, A., Goodyke, A., Nagulapally, A., Bond, J., Park, Y. and Sholler, G. S. (2020). The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Cancer Medicine 9 8144-8158.  [link] 

• Graboyes, E.M., Maurer, S., Park, Y., Marsh, C.H., McElligott, J.T., Day, T.A., Horning, J.D. and Sterba, K.R. (2020). Evaluation of a Novel Telemedicine-Based Intervention to Manage Body Image Disturbance in Head and Neck Cancer Survivors. Psycho-Oncology. [link] 

• Park, Y.* and Lin, R. (2020). Discussion on “Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O’Hagan, Biometrics. [link] 

2019

• Park, Y., Fullerton, H. and Elm, J. (2019). A Pragmatic, Adaptive Clinical Trial Design for a Rare Disease of Childhood Stroke: the FOcal Cerebral Arteriopathy Steroid, or FOCAS, trial, Contemporary Clinical Trials 86, 105852. [link] 

• Giordano, A., Liu, Y., Armeson, K., Park, Y., Erlander, M., Reuben, J., Britten, C., Kappler, C., Yeh, E. and Ethier, S. (2019). Polo-like Kinase 1 (Plk1) Inhibition Synergizes with Taxanes in Triple Negative Breast Cancer, PLoS One 14 (11): e0224420. [link] 

• Park, Y.* (2019). Review of Phase II Basket trials for Precision Medicine, Annals of Biostatistics and Biometric Applications 2(2). [link] 

• Guo, B., Park, Y. and Liu, S. (2019). A Utility-based Bayesian Phase I/II Design for Immunotherapy Trials with Progression-Free Survival Endpoint, Journal of the Royal Statistical Society: Series C 68 411-425. [link] 

Before 2019

• Doss, H. and Park, Y. (2018). An MCMC Approach to Empirical Bayes Inference and Bayesian Sensitivity Analysis via Empirical Process, The Annals of Statistics 46 1630-1663. [link] 

• Park, Y., Su, Z. and Zhu, H. (2017). Groupwise Envelope Models for Imaging Genetic Analysis. Biometrics 73 1243-1253. [link] [GENV R package][matlab code]

• Bhalla, S., Joshi, D., Bhullar, S., Kasuga, D., Park, Y. and Kay, C. N. (2013). Long-term follow-up for efficiency and safety of treatment of retinitis pigmentosa with valproic acid. British Journal of Ophthalmology 97 895-899. [link]